RESEARCH IN PULMONARY HYPERTENSION
“PHA’s research program has yielded an explosion of understanding about PH that was not known before.” – John Newman, MD, Vanderbilt University Medical Center
Thirty years ago there were no pulmonary hypertension treatments available. Through focused research there are now fourteen PH-specific treatments with more in development. But we know that your ultimate wish is for a cure, and that is why PHA will continue to support the work of researchers to extend and improve the lives of those with PH.
PHA’s Research Program
PHA’s Research Program has committed more than $8 million for PH research through the generous donations and fundraising events of the PH community, and by leveraging partnerships with the National Heart, Lung, and Blood Institute (NHLBI) and the American Thoracic Society (ATS). We have supported 70 promising researchers through four independently reviewed, cutting-edge research programs.
PHA’s Scientific Leadership Council’s Education Committee has written comprehensive fact sheets on all the treatments available for pulmonary hypertension.
Stay informed about ongoing clinical research pertaining to evaluation and treatment of pulmonary hypertension through PHA’s Clinical Trial Finder, and be sure to post information about the PH clinical trial work you are doing.
The Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics (PVDOMICS) program is a network of seven clinical sites and a data coordinating center—funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health with additional support from the Pulmonary Hypertension Association—that will perform comprehensive, deep phenotyping across all types of pulmonary hypertension (PH).